The simplest stability indicating reversed phase Isocratic HPLC and UPLC methods has been developed and validated for the determination of fluconazole in bulk and solid pharmaceutical dosage form. A SunFire C18 (250 × 4.5?mm, 5?μm particle size) column has been used for HPLC and BEH C18 (100 × 2.1?mm, 1.7?μm particle size) column used for UPLC. The Mobile phase consisted of Methanol?:?Water (70?:?30) for HPLC and Methanol?:?Water (55?:?45?v/v) for UPLC. Isocratic flow was set at 1?mL/min and 0.30?mL/min, respectively, for HPLC and UPLC. For both HPLC and UPLC system detection has been performed at 211?nm with 30°C column oven temperature (good elution was obtained at 30°C) and injection volume, respectively, 2?μL and 20?μL for HPLC and UPLC. 1. Introduction Fluconazole [2-(2,4-difluorophenyl)-1,3-bis-(1H-1,2,4-triazole-1-yl)-2-propanol] [1] is mainly used as an antifungal antibiotic [2–4] (Figure 1) is and also used to prevent yeast infections in patients who are likely to become infected, because they are being treated with chemotherapy or radiation therapy before a bone marrow transplant. Several HPLC methods were reported for the analysis of fluconazole in pharmaceutical preparations and in body fluids as plasma, serum, and human urine sample [1, 5–11]. Few of GC and HPLC methods have been reported for the determination of fluconazole in biological fluids, eye drops, and creams [12]. The UV method was also reported for syrups, capsules and intravenous solution, and microbiological assay for capsules [13]. Few of HPLC and UPLC methods have also been reported for the simultaneous determination of fluconazole and its combination dosage tablet [14, 15]. LC-MS/MS method was also reported for the determination of fluconazole in human plasma [16]. Review literature suggested that there is no single UPLC method reported for the determination of fluconazole in pharmaceutical dosage forms or in API with acidic, alkali (Figure 5), oxidative (Figure 6), thermal (Figure 7), and photo degradation (Figure 8) study. Ultraperformance liquid chromatography (UPLC) (Figure 2) is well known and widely used analytical technique for the analysis of drug products and drug substance [17]. Current work has advantages over the earlier in terms of speed and simplicity. This work also deals with the stability indicating study and forced degradation of fluconazole under conditions such as oxidation, acid hydrolysis, base hydrolysis, and thermal and photolytic stress [18]. This method was validated using both the instruments HPLC and UPLC by different parameters such as linearity,
References
[1]
K. B. Liew, G. O. K. Loh, Y. T. F. Tan, and K. K. Peh, “Development and application of simple HPLC-Uv method for fluconazole quantification in human plasma,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 4, no. 4, pp. 107–111, 2012.
[2]
N. M. Aloudah, M. A. Radwan, N. F. Al Omar, and S. Jacobs, “HPLC assay of fluconazole and its application to patients with early septic shock,” Journal of Liquid Chromatography & Related Technologies, vol. 28, no. 4, pp. 571–580, 2005.
[3]
U. K. Sarker, M. Misbahuddin, and M. A. Hossain, “Bioequivalence study of Flunac and Diflucan in healthy Bangladeshi male volunteers,” KYAMC Journal, vol. 2, no. 2, pp. 159–163, 2012.
[4]
G. Naveen Kumar Reddy, V. V. S. Rajendra Prasad, N. Devanna, and P. K. Maharana, “Development and validation of a stability indicating uplc method for determination of voriconazole in pharmaceutical formulation,” Der Pharmacia Lettre, vol. 3, no. 5, pp. 249–259, 2011.
[5]
C. E. M. de Sousa, D. C. G. Bedor, L. C. A. Sampaio Filho et al., “High-performance liquid chromatographic determination of fluconazole in plasma and its application to a bioequivalence study,” Latin American Journal of Pharmacy, vol. 30, no. 7, pp. 1432–1436, 2011.
[6]
S.-S. Kim, H.-T. Im, I.-M. Kang et al., “An optimized analytical method of fluconazole in human plasma by high-performance liquid chromatography with ultraviolet detection and its application to a bioequivalence study,” Journal of Chromatography B, vol. 852, no. 1-2, pp. 174–179, 2007.
[7]
S. A. Dgither, A. Yusuf, and M. M. Hammami, “Fluconazole: stability and analysis in human plasma by simple high performance liquid chromatography,” Fabad Journal of Pharmaceutical Sciences, vol. 34, no. 4, pp. 179–186, 2009.
[8]
F. Al-Rimawi, “Development and validation of analytical method for fluconazole and fluconazole related compounds (A, B, and C) in capsule formulations by HPLC with UV detection,” Jordan Journal of Chemistry, vol. 4, no. 4, pp. 357–365, 2009.
[9]
J. W. Hülsewede and H. Dermoumi, “Serum level determination of fluconazole by high-performance liquid chromatography and bioassay,” Zentralblatt für Bakteriologie, vol. 283, no. 4, pp. 492–496, 1996.
[10]
D. Hermawan, N. A. Md Ali, W. A. Wan Ibrahim, and M. M. Sanagi, “Analysis of fluconazole in human urine sample by high performance liquid chromatography method,” Journal of Physics: Conference Series, vol. 423, Article ID 012009, 2013.
[11]
S. R. C. J. Santos, E. V. Campos, C. Sanches, D. S. Gomez, and M. C. Ferreira, “Fluconazole plasma concentration measurement by liquid chromatography for drug monitoring of burn patients,” Clinics, vol. 65, no. 2, pp. 237–243, 2010.
[12]
A. B. Rege, J. Y. Walker-Cador, R. A. Clark, J. J. L. Lertora, N. E. Hyslop Jr., and W. J. George, “Rapid and sensitive assay for fluconazole which uses gas chromatography with electron capture detection,” Antimicrobial Agents and Chemotherapy, vol. 36, no. 3, pp. 647–650, 1992.
[13]
P. Sadasivudu, N. Shastri, and M. Sadanandam, “Development and validation of RP-HPLC and UV methods of analysis for fluconazole in pharmaceutical solid dosage forms,” International Journal of ChemTech Research, vol. 1, no. 4, pp. 1131–1136, 2009.
[14]
H. M. Lotfy, A. A. A. B. Abdel-Aleem, and H. H. Monir, “Stability-indicating high performance liquid chromatographic determination of fluconazole in the presence of its oxidative degradation product—kinetic and stress study,” Journal of Liquid Chromatography and Related Technologies, vol. 36, no. 8, pp. 1013–1029, 2013.
[15]
D. B. Meshram, S. B. Bagade, and M. R. Tajne, “Simple HPLC method for simultaneous estimation of fluconazole and tinidazole in combined dose tablet,” Journal of Chromatographic Science, vol. 47, no. 10, pp. 885–888, 2009.
[16]
D. Wu, K. C. Wade, D. J. Paul, and J. S. Barrett, “A rapid and sensitive LC-MS/MS method for determination of fluconazole in human plasma and its application in infants with candida infections,” Therapeutic Drug Monitoring, vol. 31, no. 6, pp. 703–709, 2009.
[17]
B. Dabhi, Y. Jadeja, M. Patel, H. Jebaliya, D. Karia, and A. Shah, “Method development and validation of a stability-indicating RP-HPLC method for the quantitative analysis of dronedarone hydrochloride in pharmaceutical tablets,” Scientia Pharmaceutica, vol. 81, no. 1, pp. 115–122, 2013.
[18]
R. Yanamandra, A. Chaudhary, S. R. Bandaru et al., “Development of a RP-UPLC method for the simultaneous analysis of secnidazole, fluconazole, and azithromycin: application in pharmaceuticals and human serum,” International Journal of PharmTech Research, vol. 3, no. 2, pp. 1198–1207, 2011.
[19]
International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Validation of Analytical Procedures: Definitions and Terminology, Q2A, Geneva, Switzerland, 1996.
[20]
International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Validation of Analytical Procedures: Methodology, Q2B, Pharmaceutical Technology, Geneva, Switzerland, 1996.